• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Agios Appoints Dr. Jay Backstrom to Board of Directors

    7/8/25 7:00:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGIO alert in real time by email

    CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the appointment of Jay Backstrom, M.D., M.P.H., to its Board of Directors, effective immediately. Dr. Backstrom is an accomplished healthcare executive with a proven track record of advancing clinical programs across a range of therapeutic areas, including rare diseases, to regulatory approval.

    "We are thrilled to welcome Jay to the Agios Board of Directors," said Brian Goff, Chief Executive Officer, Agios. "His deep scientific insight, extensive regulatory expertise, and strategic business leadership come at a pivotal time for Agios, as we work to maximize the full potential of PYRUKYND (mitapivat), our first-in-class PK activator, and advance our growing pipeline of rare disease medicines."  

    Dr. Backstrom brings decades of leadership experience spanning large pharmaceutical companies, mid-sized biotech firms, and early-stage biopharma organizations. Most recently, as President and Chief Executive Officer of Scholar Rock, he led a strategic pipeline review and advanced the company's lead spinal muscular atrophy program through Phase 3 development and regulatory filings in both the U.S. and European Union. Previously, he served as Executive Vice President of Research and Development at Acceleron Pharma, which was acquired by Merck in 2021, and as Chief Medical Officer and Head of Global Regulatory Affairs at Celgene Corporation. At Celgene, Dr. Backstrom led key efforts to expand the pipeline and played a pivotal role in advancing clinical programs that led to regulatory approvals in beta thalassemia and myelodysplastic syndromes.

    "It is an honor to join Agios' Board of Directors and work alongside such a talented group as the company enters its next phase of commercial growth and innovation," said Dr. Backstrom. "Agios is laser-focused on redefining the future of rare disease treatment, driven by a maturing and expanding pipeline of promising innovative medicines. Having followed the company's progress and collaborated with several members of the leadership team and Board in the past, I am eager to contribute to advancing its inspiring mission."

    Dr. Backstrom will serve on Agios' Science and Technology Committee.

    About Agios

    Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company's website at www.agios.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the expected benefits of Dr. Backstrom's service on the board of directors of Agios and the potential benefits of the company's preclinical, clinical and commercial development plans. The words "anticipate," "expect," "goal," "hope," "milestone," "plan," "potential," "possible," "strategy," "will," "vision," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including, without limitation: risks and uncertainties related to the impact of pandemics or other public health emergencies to Agios' business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios' results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios' ability to establish and maintain key collaborations; uncertainty regarding any royalty payments related to the sale of its oncology business or any milestone or royalty payments related to its in-licensing of TMPRSS6 siRNA, and the uncertainty of the timing of any such payments; uncertainty of the results and effectiveness of the use of Agios' cash and cash equivalents; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios' public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    Contacts:

    Investor Contact

    Morgan Sanford, Vice President, Investor Relations

    Agios Pharmaceuticals

    [email protected]

    Media Contact

    Eamonn Nolan, Senior Director, Corporate Communications

    Agios Pharmaceuticals

    [email protected]



    Primary Logo

    Get the next $AGIO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AGIO

    DatePrice TargetRatingAnalyst
    2/24/2025$58.00Buy
    H.C. Wainwright
    10/16/2024Sector Outperform
    Scotiabank
    10/10/2024$51.00Outperform
    Raymond James
    9/27/2024$60.00 → $56.00Outperform → Market Perform
    Leerink Partners
    2/8/2024Overweight
    Cantor Fitzgerald
    2/3/2023$41.00Overweight
    Piper Sandler
    11/17/2022$17.00 → $32.00Sell → Neutral
    Goldman
    7/27/2022$33.00Mkt Perform → Outperform
    SVB Leerink
    More analyst ratings

    $AGIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for PYRUKYND issued to AGIOS PHARMACEUTICALS INC

      Submission status for AGIOS PHARMACEUTICALS INC's drug PYRUKYND (ORIG-1) with active ingredient MITAPIVAT has changed to 'Approval' on 02/17/2022. Application Category: NDA, Application Number: 216196, Application Classification: Type 1 - New Molecular Entity

      2/17/22 2:39:08 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for TIBSOVO issued to AGIOS PHARMS INC

      Submission status for AGIOS PHARMS INC's drug TIBSOVO (SUPPL-7) with active ingredient IVOSIDENIB has changed to 'Approval' on 03/18/2021. Application Category: NDA, Application Number: 211192, Application Classification: Labeling

      3/22/21 5:06:31 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Agios Appoints Dr. Jay Backstrom to Board of Directors

      CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the appointment of Jay Backstrom, M.D., M.P.H., to its Board of Directors, effective immediately. Dr. Backstrom is an accomplished healthcare executive with a proven track record of advancing clinical programs across a range of therapeutic areas, including rare diseases, to regulatory approval. "We are thrilled to welcome Jay to the Agios Board of Directors," said Brian Goff, Chief Executive Officer, Agios. "His deep scientific insight, extensive regulatory expertise, and s

      7/8/25 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders

      PYRUKYND® (mitapivat) is a first-in-class pyruvate kinase (PK) activator, approved by the European Commission for adults with PK deficiency The agreement includes commercialization and distribution rights for potential future indications Furthered by this partnership with Agios, Avanzanite is setting a new paradigm in biotech commercial and distribution partnerships, and in how orphan medicines reach patients across Europe Avanzanite Bioscience B.V. ("Avanzanite"), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (NASDAQ:AGI

      6/9/25 8:40:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025

      CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 8:40 a.m. ET. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be archived on the company's website for at least two weeks following the presentation. About AgiosAgios is the pioneering leader in PK activation and is

      5/28/25 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Agios Appoints Dr. Jay Backstrom to Board of Directors

      CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the appointment of Jay Backstrom, M.D., M.P.H., to its Board of Directors, effective immediately. Dr. Backstrom is an accomplished healthcare executive with a proven track record of advancing clinical programs across a range of therapeutic areas, including rare diseases, to regulatory approval. "We are thrilled to welcome Jay to the Agios Board of Directors," said Brian Goff, Chief Executive Officer, Agios. "His deep scientific insight, extensive regulatory expertise, and s

      7/8/25 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, portfolio and program strategy and business development as Chief Business Officer of Agios Pharmaceuticals (NASDAQ:AGIO), and previously held strategic product and portfolio roles at Biogen (NASDAQ:BIIB). In her role at Cardurion, she will be responsible for leading corporate development, bus

      1/8/25 8:00:00 AM ET
      $AGIO
      $BIIB
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Agios Appoints Catherine Owen to Board of Directors

      – John Maraganore Completes Tenure on Agios Board After Nearly a Dozen Years of Service – – Kaye Foster to Be Appointed Lead Independent Director – CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that Catherine Owen has been appointed to its board of directors, effective June 13, 2023. Agios also announced that, following a collaborative succession planning process, John Maraganore, Ph.D., who has served as a valuable board member and advisor to the company since 2011, will step down from the board of directors, effective immediately, and

      5/25/23 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Financials

    Live finance-specific insights

    See more
    • Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 – CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kin

      5/1/25 6:30:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025

      CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET to report its first quarter 2025 financial results and business highlights. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be available on the company's website approximately two hours after the event. About AgiosAgios is the pioneering leader in PK act

      4/17/25 7:00:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      – Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates; PDUFA Goal Date of September 7, 2025 – – Completed Enrollment for Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Results Expected in Late 2025, with Potential U.S. Commercial Launch in 2026 – – Early- and Mid-Stage Pipeline Offers Strong Foundation for Innovation and Growth – – PYRUKYND Net Revenue of $10.7 Million in Q4; Cash, Cash Equivalents and Marketable Securitie

      2/13/25 6:31:00 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Gheuens Sarah exercised 11,914 shares at a strike of $25.01 and sold $452,601 worth of shares (11,914 units at $37.99) (SEC Form 4)

      4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

      7/11/25 4:59:12 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Backstrom Jay T.

      4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

      7/10/25 4:14:25 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Backstrom Jay T.

      3 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

      7/10/25 4:12:22 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    SEC Filings

    See more
    • Agios Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

      8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

      7/8/25 7:01:27 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Agios Pharmaceuticals Inc.

      SCHEDULE 13G - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

      7/7/25 7:32:17 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Agios Pharmaceuticals Inc.

      S-8 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

      6/18/25 4:41:20 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Agios Pharma with a new price target

      H.C. Wainwright initiated coverage of Agios Pharma with a rating of Buy and set a new price target of $58.00

      2/24/25 7:01:42 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Agios Pharma

      Scotiabank initiated coverage of Agios Pharma with a rating of Sector Outperform

      10/16/24 8:38:23 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on Agios Pharma with a new price target

      Raymond James resumed coverage of Agios Pharma with a rating of Outperform and set a new price target of $51.00

      10/10/24 8:30:27 AM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc.

      SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

      11/14/24 3:44:53 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc.

      SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

      11/8/24 2:40:47 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc. (Amendment)

      SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

      2/14/24 2:21:13 PM ET
      $AGIO
      Biotechnology: Pharmaceutical Preparations
      Health Care